CFN Media Group interviews Dr. Sharon Rozenblat, Advisory Board Member for OWC Pharmaceutical Research Corp. (OTCQB : OWCP). Dr. Rozenblat is largely responsible for the development of the company's active cannabinoid topical cream designed to treat psoriasis. OWC Pharmaceuticals owns 100% of One World Cannabis Ltd., which was formed to apply pharmaceutical research protocols and disciplines to the global medical cannabis space. Dr. Yehuda Baruch spearheads the company's research efforts after serving as the head of the Israeli Ministry of Health's Medical Cannabis Program over 10 years, overseeing clinical trials, regulatory compliance, and other industry-wide issues. OWC Pharmaceuticals is focused on the development of two delivery systems: A proprietary, cannabinoid-enriched sublingual tablet and a proprietary topical compound. Between these, the company plans to address several multi-billion dollar end markets including serious medical conditions like multiple myeloma, post-traumatic stress disorder, fibromyalgia, and psoriasis, along with hundreds of additional addressable indications down the road.